PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2024Cancer Research

Abstract LB042: A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMeijie TianKJKatrina JiaJWJerry T. Wu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tian et al. (2024) studied this question.

synapsesocial.com/papers/68e70461b6db64358767e9fdhttps://doi.org/10.1158/1538-7445.am2024-lb042
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 4015: Improvement of CAR T cell potency against low-density targets like L1CAM and FGFR4 in rhabdomyosarcoma2024 · 1 citations
  2. 2Abstract PD3-05: Targeting FGFR4 with an antibody-drug conjugate in hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer progressing to CDK4/6 inhibitors and endocrine therapy2026
  3. 3Abstract LB268: Preclinical development of 3H-10000, a novel vedotin antibody-drug conjugate for treatment of FGFR2b-expressing cancers2026
  4. 4Abstract 2630: MRG008: A novel EGFR and 5T4 bispecific antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies.2026
  5. 5Abstract 6944: Preclinical evaluation of a novel and highly differentiated FGFR2b-targeting ADC with low risk of ocular toxicity2026